TRACON Pharmaceuticals Inc. Q1 2023 Earnings Call

That's not lost on companies, especially in this environment, where capital efficiency is so important so.

Again, I can't exactly give you a timetable, but I would say that there is extreme interest in the platform.

That's regard as a significant part of the trick on value proposition as is our late stage clinical asset.

Okay. Thanks, Charles and my last question is just concerning the.

AD hoc analysis in the second quarter.

Yes.

Since it's not based on futility, what can you actually tell us. After this AD hoc analysis. We you just tell us that that study is going to continue as planned or.

Is there any.

A data point.

We'll be releasing.

No great point, Ed, Yes, our goal with the AD hoc analysis, you mentioned, that's coming up this quarter would be to be able to report similar to what we reported in December that the drug is tolerated a single agent and tolerated when combined with <unk> and that we remain with a double digit response rate in each cohort knowing that we won't.

Have two months of data on every single patient enrolled at this time.

But we will be able to report on the available data for patients.

But it will be short of 46 patients in each cohort to be clear.

Okay. Thanks for taking my questions.

Appreciate the questions. Thank you.

Thank you.

As a reminder to ask a question. Please press star one on your phone and wait for your name to be announced to withdraw your question. Please press star one again.

Next question.

Our next question will come from Joel Beatty of Baird. Your line is open.

Great. Thanks for the update and for taking the question. The first one is a follow up on the efficacy analyses from our analysis is coming from <unk> in this quarter next quarter from an efficacy point of view I mean, when we think about both of them as similar to the <unk>.

<unk> update and the amount of data provided in the main difference is just kind of a number of patients or are there are there any differences in the level of detail that will be provided to to consider.

Hi, Joe I appreciate the question. So the formal interim efficacy analysis in third quarter is a very.

Regimented data set if you will so it's 46 patients in each cohort and each of those patients is followed for at least three months. So they each have at least two scans on study. So that you can get a reasonable.

Understanding of what the general response rate will be knowing it's still could grow with time, but youll at least have the ability to assess response rate based on at least two scans in each of those 46 patients.

The assessment this quarter will not have that degree of follow up on these patients. So we'll have all the available data.

Not every scan will be have undergone central review for example in the second quarter analysis. So what we expect to report his data on patients up to 46 patients.

Knowing that many of them may not have been followed for three months and knowing that not all of those patients will have had two scans nor will all of those scans been assessed by Central review. So we'll caveat. If you will be the expected press release in quarter, two with respect to safety, but also efficacy to get an understanding of what the response rate is in <unk>.

<unk> sort of had for instance, two scans knowing that not every scan rope undergone central review and knowing that that denominator will not be 46 patients as it will be in third quarter.

Yes, I appreciate that and then.

Question on <unk>.

Potential collaborations regarding the CRO independent model.

In light of the <unk> arbitration.

Somewhat lengthy is there a way to kind of inform the future agreements regarding the CIO independent model in such a way to kind of help.

Minimize the possibility.

The possibility of kind of future arbitration that might be.

Be cumbersome for our trade kind of as well as potentially deteriorate potential partners.

Yes, I think we have multiple partners, Joe and going forward, we expect to work with partners as well that.

It will be similar to the partners. We are currently engaged with includes alphabet of oncology includes three medicines includes <unk> biopharma.

I think.

We are an excellent partner and I think the efficiency with which we conduct trials in the manner of this team makes us incredibly attractive partner for people who are looking.

Looking to accelerate the timeline decrease the cost and improve the quality of their clinical trials.

I would point out in the past we had collaborations around our platform with companies like Johnson <unk> Johnson and.

That was a very fruitful productive collaboration for both us and for them.

Great. Thank you.

I appreciate the question Joel Thank you.

Thank you.

Again to ask a question. Please press star one on your phone and wait for your name to be announced to withdraw. Your question. Please press star one again standby.

Standby as we compile the Q&A roster.

I am seeing no further questions in the queue I would now like to turn the conference back to Dr. Charles <unk> for closing remarks.

I'd like to thank the participants for your time and attention and we look forward to speaking and updating you. After next quarterly call have a good day.

This concludes today's conference call. Thank you all for participating you may now disconnect and have a pleasant day.

Okay.

[music].

Okay.

[music].

Okay.

Okay.

[music].

Yeah.

[music].

[music].

Sure.

Yes.

[music].

Yeah.